Search Results - "proteins"

RAS and RAF signaling in melanoma biology and therapies /

Subjects: Get full text
Series

RAS and RAF signaling in melanoma biology and therapies /

Subjects: Get full text
Series

RAS and RAF signaling in melanoma biology and therapies /

Subjects: Get full text
Series

Cytochrome b5 reductase deficiency and hereditary methemoglobinemia

Subjects: Get full text
Series

Cytochrome b5 reductase deficiency and hereditary methemoglobinemia

Subjects: Get full text
Series

Cytochrome b5 reductase deficiency and hereditary methemoglobinemia

Subjects: Get full text
Series

The molecular biology of Huntington's disease

Table of Contents: “…Contents: Clinical presentations of HD -- Pathological features -- Genetic basis -- Trinucleotide repeat expansion mutation -- Huntingtin protein and cell damage -- Abnormal protein aggregation -- Transcriptional abnormalities -- Raised levels of reactive oxygen species -- Future directions for therapeutic intervention -- siRNA approaches -- Induction of autophagy.…”
Get full text
Series

The molecular biology of Huntington's disease

Table of Contents: “…Contents: Clinical presentations of HD -- Pathological features -- Genetic basis -- Trinucleotide repeat expansion mutation -- Huntingtin protein and cell damage -- Abnormal protein aggregation -- Transcriptional abnormalities -- Raised levels of reactive oxygen species -- Future directions for therapeutic intervention -- siRNA approaches -- Induction of autophagy.…”
Get full text
Series

The role of MAPT (Tau) in neurodegenerative disease one bullet with many triggers /

Table of Contents: “…Contents: Medical importance of tauopathies -- Microtubule Associated Protein Tau (MAPT) is incorporated into neurofibrillary lesions -- Mutations in the MAPT gene give rise to Frontotemporal dementia with parkinsonism (FTDP-17) -- Common variability in the MAPT, the so-called H1/H1 haplotype and sporadic tauopathies -- Progressive supranuclear Palsy and Cortico-basal degeneration -- Constitutive and conditional transgenic mouse models of tauopathy -- The JNPL3 mouse model of tauopathy -- Neurofibrillary tau pathology in the JNPL3 mice -- A-beta and MAPT pathologies can interact during the development of Alzheimer's disease -- Conditional rTg4510 model of tauopathy -- Major mechanism of neurodegeneration in tauopathy -- Potential therapeutic applications.…”
Get full text
Series

The role of MAPT (Tau) in neurodegenerative disease one bullet with many triggers /

Table of Contents: “…Contents: Medical importance of tauopathies -- Microtubule Associated Protein Tau (MAPT) is incorporated into neurofibrillary lesions -- Mutations in the MAPT gene give rise to Frontotemporal dementia with parkinsonism (FTDP-17) -- Common variability in the MAPT, the so-called H1/H1 haplotype and sporadic tauopathies -- Progressive supranuclear Palsy and Cortico-basal degeneration -- Constitutive and conditional transgenic mouse models of tauopathy -- The JNPL3 mouse model of tauopathy -- Neurofibrillary tau pathology in the JNPL3 mice -- A-beta and MAPT pathologies can interact during the development of Alzheimer's disease -- Conditional rTg4510 model of tauopathy -- Major mechanism of neurodegeneration in tauopathy -- Potential therapeutic applications.…”
Get full text
Series

Complement and lupus

Subjects: Get full text
Series

Pyruvate kinase deficiency

Subjects: Get full text
Series

Astrocytes and Alexander disease the first, but not last, primary astrocyte disease /

Subjects: “…Glial Fibrillary Acidic Protein metabolism.…”
Get full text
Series

Complement in PNH and other hemolytic anaemias part 1 of 3 /

Subjects: Get full text
Series

CLL novel prognostics, and updates on therapy - part 2 of 2 /

Subjects: Get full text

Complement deficiencies in humans

Subjects: Get full text
Series

Complement and lupus

Subjects: Get full text
Series (Complement system)
Series (The Immune System)

Complement and lupus

Subjects: Get full text
Series (Complement system)
Series (The Immune System)

Abeta toxicity Part 1 /

Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)

Frontotemporal dementia

Subjects: Get full text
Series